• To reduce the size and duration, and increase the precision of human clinical trials by mechanistic biomarker-based patient stratification and at least two third reduction of the numbers needed to treat (NN2T) for a cluster of cerebro-cardiovascular disease phenotypes
  • To significantly reduce animal testing and enhance its precision, reproducibility and relevance
  • To provide libraries and databases of virtual patients with cerebro-cardiovascular disease phenotypes for re-use in pre- and post-competitive testing of biomedical products
  • To lower the development costs and/or shorten the proof-of-concept and time-to-market by immediate repurposing registered drugs targeting a common mechanism of cerebro-cardiovascular disease phenotypes
  • To validate our approach by achieving clinical proof-of-concept in up to three relevant and high medical-need indications of cerebro-cardiovascular disease phenotypes
  • To provide to the R&D community open access in silico models for similar scenarios of common mechanism-based drug repurposing incorporating stratification algorithms for gender and age